Highlights from ASCO
June 5, 2023
Dr Claudio Cerchione summarised the educational session on the management of multiple myeloma in special patient populations, such as elderly and patients with renal failure.
From 2 June till 6 June 2023: HIGHLIGHTS FROM ASCO
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2023 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the support of:
Daily highlights
Project in the spotlight
The IMROZ trial
July 15, 2024
Dr Marie Vercruyssen, a haematologist at the Institut Jules Bordet in Brussels, summarised the outcomes of the IMROZ trial, which evaluated the addition of the anti-CD38 monoclonal antibody isatuximab to
Results from the screened iSTOPMM study
July 10, 2024
Dr Sigrún Thorsteinsdóttir, a haematologist at Rigshospitalet in Copenhagen, Denmark, also holds a position as a postdoctoral researcher in the iStopMM study at the University of Iceland. The iSTOPMM study
Vaccination against mutated RAS in MM: the phase I/II TG01 study
July 9, 2024
Dr Hanne Norseth, a haematologist at the Oslo Myeloma Center in Norway, presented the results of the phase I/II TG01 study. This study evaluates the safety and efficacy of the
The BENEFIT trial: Isa-VRd in non-frail patients with NDMM TI
July 9, 2024
At the EHA 2024 conference, Prof Dr Xavier Leleu, Head of the Myeloma Clinic and Department of Haematology at the University Hospital of Poitiers (France), presented the results of the
New treatment combinations in RRMM patients
July 9, 2024
Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, highlights the necessity for novel treatment combinations in lenalidomide-refractory MM patients. Belantamab
How to treat frail patients with multiple myeloma?
July 3, 2024
During EHA 2024, an entire session was dedicated to the management of difficult to treat multiple myeloma (MM) populations. In this session, Dr Claudia Stege, haematologist at the Erasmus Medical
Blinatumomab added to prephase and consolidation therapy for adult B-ALL patients
July 3, 2024
During EHA 2024, Dr Anita Rijneveld, haematologist at the Erasmus Medical Center Cancer Institute in Rotterdam, presented the final results of the phase II HOVON-146 study. This study evaluated the
CAR-T cell therapy as second line treatment for high-risk multiple myeloma (MM)
July 3, 2024
During EHA 2024, Prof Dr Xavier Leleu, Head of the Myeloma Clinic and Head of the Department of Haematology at the University Hospital of Poitiers (France), presented the results of
In-depth stories
The IMROZ trial
July 15, 2024
Dr Marie Vercruyssen, a haematologist at the Institut Jules Bordet in Brussels, summarised the outcomes of the IMROZ trial, which evaluated the addition of the anti-CD38 monoclonal antibody isatuximab to
Results from the screened iSTOPMM study
July 10, 2024
Dr Sigrún Thorsteinsdóttir, a haematologist at Rigshospitalet in Copenhagen, Denmark, also holds a position as a postdoctoral researcher in the iStopMM study at the University of Iceland. The iSTOPMM study
Vaccination against mutated RAS in MM: the phase I/II TG01 study
July 9, 2024
Dr Hanne Norseth, a haematologist at the Oslo Myeloma Center in Norway, presented the results of the phase I/II TG01 study. This study evaluates the safety and efficacy of the
The BENEFIT trial: Isa-VRd in non-frail patients with NDMM TI
July 9, 2024
At the EHA 2024 conference, Prof Dr Xavier Leleu, Head of the Myeloma Clinic and Department of Haematology at the University Hospital of Poitiers (France), presented the results of the
New treatment combinations in RRMM patients
July 9, 2024
Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, highlights the necessity for novel treatment combinations in lenalidomide-refractory MM patients. Belantamab
How to treat frail patients with multiple myeloma?
July 3, 2024
During EHA 2024, an entire session was dedicated to the management of difficult to treat multiple myeloma (MM) populations. In this session, Dr Claudia Stege, haematologist at the Erasmus Medical
Blinatumomab added to prephase and consolidation therapy for adult B-ALL patients
July 3, 2024
During EHA 2024, Dr Anita Rijneveld, haematologist at the Erasmus Medical Center Cancer Institute in Rotterdam, presented the final results of the phase II HOVON-146 study. This study evaluated the
CAR-T cell therapy as second line treatment for high-risk multiple myeloma (MM)
July 3, 2024
During EHA 2024, Prof Dr Xavier Leleu, Head of the Myeloma Clinic and Head of the Department of Haematology at the University Hospital of Poitiers (France), presented the results of
Poster selection
QuANTUM-First: Efficacy by age in newly diagnosed FLT3-ITD–positive AML
July 1, 2024
Dr Pau Montesinos, a haematologist at the Hospital Universitario y Politècnico La Fe in Valencia, Spain, presented a post hoc analysis of the phase 3 QuANTUM-First study. This analysis evaluated
The Impact of Isatuximab HGG in R/R MM patients
December 13, 2023
Dr Cesar Rodriguez, affiliated with Mount Sinai in New York, presents a research study examining the impact of isatuximab (Isa) on the occurrence of hypogammaglobulinemia (HGG) and the concomitant risk
AML real world evidence initiative: venetoclax versus control in patients unfit for intensive chemotherapy
December 13, 2023
In this study, Dr Aaron Goldberg from the Memorial Sloan Kettering Cancer Center presents a comparative analysis of outcomes and healthcare research utilization in patients with AML treated with venetoclax
ELEVATE-TN: Impact of first-year dose modifications in treatment-naive CLL patients treated with acalabrutinib
December 13, 2023
Prof George Follows, a consulting haematologist from Nuffield Health Cambridge Hospital, presents a post-hoc analysis of the ELEVATE-TN trial, a prospective, randomized study involving treatment-naïve elderly CLL patients. Patients were
cfDNA as alternative to bone marrow cells for molecular diagnostics and MM monitoring
December 13, 2023
In this presentation, Dory Abelman, a PhD candidate at the Princess Margaret Cancer Centre, University of Toronto, assesses the concordance of molecular profiles between cancer cells derived from bone marrow
The SKylaRK trial
December 13, 2023
Dr Betsy O’Donnell, a haematologist at the Dana-Farber Cancer Institute (US), presents the findings from the SKylaRK trial, a phase 2 study in NDMM patients eligible for transplantation, who received
Pragmatic recommendations for treating patients with myelofibrosis, particularly those experiencing cytopenias
December 12, 2023
Prof Claire Harrison, a haematologist at Guy’s and St. Thomas’ Hospital in London (UK), presents collaborative efforts involving colleagues and patients to offer pragmatic recommendations for treating patients with myelofibrosis,
The REMNANT study: will treatment at MRD relapse improve survival in MM?
December 12, 2023
Dr Frida Bugge Askeland, associated research doctor and PhD student at the Oslo Myeloma Center in Norway outlined the REMNANT study.
The REMNANT study aims to assess whether addressing MRD relapses